Results 251 to 260 of about 3,265,867 (293)
Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis [PDF]
Lancet, The, 2015 BackgroundTreatment with aspirin and a P2Y12 inhibitor is commonly used in patients with cardiovascular disorders. The overall effect of such treatment on all-cause mortality is unknown. In the Dual Antiplatelet Therapy (DAPT) Study, continuation of dual
Philippe Gabriel Steg, Sammy Elmariah
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dual antiplatelet therapy duration
Current Opinion in Cardiology, 2011To address the evidence, or lack thereof, of dual antiplatelet therapy (DAPT) duration in the percutaneous coronary intervention (PCI) setting.The most recent guidelines on DAPT in the PCI setting are rather discordant about the duration of therapy and refer to results of studies which are often controversial.
Giuseppe, Musumeci +2 more
openaire +2 more sources
Dual antiplatelet therapy with clopidogrel and aspirin
American Journal of Health-System Pharmacy, 2008Dual antiplatelet therapy with clopidogrel and aspirin is reviewed.Several studies have evaluated the effectiveness of clopidogrel, aspirin, or the combination of these agents in a variety of patient populations. The results of these studies have helped determine the role of clopidogrel and aspirin in evidence-based medicine.
Joshua, Sullivan, Naseem, Amarshi
openaire +2 more sources
The Duel between Dual Antiplatelet Therapies
New England Journal of Medicine, 2013Current guidelines for patients who are being considered for percutaneous coronary intervention (PCI) recommend dual antiplatelet therapy (aspirin and a platelet adenosine diphosphate [ADP]–receptor antagonist) to minimize periprocedural complications.1 Clopidogrel is usually administered in patients with stable angina,2 whereas patients with an acute ...
Richard A, Lange, L David, Hillis
openaire +2 more sources
Gastrointestinal protection with dual antiplatelet therapies
BMJ, 2018Dalal and colleagues provide a concise update on the pharmacological and behavioural management of patients after a myocardial infarction.1 This otherwise holistic article does not mention the risks and means of prevention of gastrointestinal bleeding, which is associated with poorer prognosis in this patient population. Aspirin monotherapy increases
openaire +2 more sources
Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy
The American Journal of Cardiology, 2015Several observational studies, randomized controlled trials, and meta-analyses suggested that pretreatment with clopidogrel in addition to aspirin could reduce the rate of ischemic events, especially in the setting of acute coronary syndromes. Newer P2Y12 inhibitors like prasugrel and ticagrelor, which provide faster and stronger platelet inhibition ...
Leonardo De Luca +3 more
openaire +3 more sources
Stent Thrombosis and Duration of Dual Antiplatelet Therapy
Current Pharmaceutical Design, 2010Stent thrombosis (ST) is a rare complication following coronary stenting; however given the associated serious consequences, in particular death and myocardial infarction, it remains a source of considerable concern for cardiologists. Although no differences have been found between drug-eluting stents (DES) and bare-metal stents (BMS) in terms of early
Alfonso, Ielasi +2 more
openaire +2 more sources
Dual antiplatelet therapy after coronary stenting
Expert Opinion on Pharmacotherapy, 2016Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the mainstay of pharmacotherapy in patients undergoing coronary stenting. Currently, three P2Y12 receptor inhibitors are approved for clinical use, including clopidogrel, prasugrel, and ticagrelor, with the latter two being preferred in patients presenting with an ...
Yongwhi, Park +3 more
openaire +2 more sources
Dual Antiplatelet Therapy After Stent Implantation
JAMA, 2014The Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) trial1 contributes to the body of evidence supporting an improved safety profile of second-generation drug-eluting stents compared with first-generation models.2 However, although it is tempting to simplify the
Stephen J, Greene +2 more
openaire +2 more sources
Dual Antiplatelet Therapy or Dual Pathway Inhibition
Thrombosis and Haemostasis, 2023Shinya Goto, Shinichi Goto
openaire +2 more sources